Since being approved, Wegovy's popularity has soared, to the point where the drug has made its maker, Novo Nordisk -- for ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Eli Lilly (NYSE: LLY) is preparing to start Phase III trials of its experimental obesity therapy eloralintide by year-end, ...

Eli Lilly's GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company's weight loss drug success. Weight loss drugs are set to ...

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

Indianapolis-based Eli Lilly and Co. is acquiring Cambridge, Mass.-based CoLucid Pharmaceuticals for $960 million, the Indianapolis Business Journal reports. Here’s what you should know. 1. Eli Lilly ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

South Korean clinical-stage biotech ABL Bio has entered license, research and collaboration agreement with US pharma major ...

Eli Lilly partners with NVIDIA to build the world’s most powerful AI supercomputer in pharma, accelerating drug discovery and manufacturing innovation.

Eli Lilly's (NYSE: LLY) share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House. However, it's a much different story so far in Trump's ...